Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Dec 01, 2021 12:42pm
144 Views
Post# 34185574

RE:RE:RE:RE:RE:RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics

RE:RE:RE:RE:RE:RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics With Roche’s HER2-positive breast cancer drug Herceptin (trastuzumab) patent expired in 2019 the company along with others are accelerating to develop antibody-drug conjugates (ADCs) incorporating trastuzumab into a proprietary combination oncology product.

Consequently Roche appears to have consulted ONCY and SOLTI to initiate cohort 6 in the AWARE-1 study to further determine the synergy of trastuzumab plus ONCY's oncolytic virus pelareorep in the treatment of HER2 positive early stage breast cancer. It has already been reported that this comination is effective in the treatment of HER2 positive gastric cancers.

ONCY has already informed its shareholders that pelreorep is being studied with bispecifics, now perphaps ADCs are also on the list as the newly announced cohort 6 has been opened under the AWARE-1 study.

Such work will certainly peak Gilead's interest especially now with Gilead's acquisition of Immunomedics.


<< Previous
Bullboard Posts
Next >>